Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Adjuvant Study 2 (SSG XVIII)

Novartis · Phase 3 · Completed · Enrollment 400

NCT00116935

ArmPopulationDoseEstimandComparatorEfficacy
Imatinib 400 mg for 36 monthsresected high-risk KIT positive GIST400 mgITTimatinib for 12 monthsrecurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 monthsoverall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months